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Abstract
Introduction: Malaria continues to be one of the major public health problems in Africa, Asia and Latin America. Artemisinin
derivatives (ARTs; artesunate, artemether, and dihydroartemisinin) derived from the herb, Artemisia annua, are the most
effective antimalarial drugs available providing rapid cures. The World Health Organisation (WHO) has recommended that
all antimalarials must be combined with an artemisinin component (artemisinin-based combination therapy; ACT) for use as
first line treatment against malaria. This class of drugs is now first-line policy in most malaria-endemic countries. Reports of
ad hoc surveys from South East Asia show that up to 50% of the artesunate currently sold is counterfeit. Drug quality is
rarely assessed in resource poor countries in part due to lack of dedicated laboratory facilities which are expensive to build,
equip and maintain. With a view to address this unmet need we developed two novel colour reaction assays that can be
used in the field to check the quality of ARTs.
Methods and Findings: Our assays utilise thin layer chromatography silica gel sheets and 2, 4 dinitrophenylhydrazine or 4-
Benzoylamino-2, 5-dimethoxybenzenediazonium chloride hemi (zinc chloride) salt as the reagents showing a pink or blue
product respectively only in the presence ARTs. We are able to detect as low as 10% of ARTs in ACTs (WINTHROP -
artesunate/amodiaquine, CoartemH-artemether/lumefantrine and Duocortexcin - dihydroartemisinin/piperaquine). The
assays have been validated extensively by testing eighty readily accessible and widely used drugs in malaria endemic
countries. None of the other antimalarial drugs or a range of commonly used excipients, antiretroviral drugs or other
frequently used drugs from the WHO essential drugs list such as analgesics or antibiotics are detected with our assays.
Conclusions: Our two independent assays requiring no specialist training are specific, simple to use, rapid, robust,
reproducible, inexpensive and, have successfully resulted in detecting two counterfeit drugs within a small scale screening
survey of over 100 declared artemisinin-containing drugs collected from various Asian and African countries. These
promising results indicate that the assays will provide a useful first test to assure the quality of the ACTs formulations in
resource poor malaria endemic areas when there is an absence of dedicated medicines quality laboratory facilities.
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Introduction
Malaria continues to be one of the major public health
problems in Africa, Asia and Latin America. Plasmodium falciparum
(Welch, 1897) malaria is estimated to be the direct cause of 213.5
million clinical episodes in Africa and over 1 million deaths per
year, mostly in children [1,2]. New strains of the potentially fatal
form of malaria, Plasmodium falciparum, have emerged that have
developed resistance to most first- and second-line antimalarial
drugs. Artemisinin derivatives (ARTs; artesunate =AS, dihy-
droartemisinin =DHA, artemether =AM, arteether =AE) de-
rived from the herb, quing hao, sweet wormwood or Artemisia annua
L (Asteraceae), are the most effective antimalarial drugs available
providing rapid cures. The WHO has recommended that all
antimalarials must be combined with an artemisinin component
(artemisinin-based combination therapy; ACT) for use as first line
treatment against malaria, and this class of drugs is now first-line
policy in most malaria-endemic countries [3].
The increase in demand for ACTs, where the artemisinin derivative
component is the expensive part, places these drugs at the inevitable
risk of being counterfeited or produced at lower cost using substandard
technology. Formulations may contain insufficient active ingredients,
no active ingredients, the wrong (possibly toxic) ingredients, or fail to
dissolve [4]. Additionally quality of the formulations may suffer as a
result of being transported and stored inappropriately. Fake and
substandard drugs are a great and growing problem.
There is evidence of the widespread distribution of fake
artesunate tablets in SE Asia, resulting in fatalities among people
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who would have otherwise survived their malaria infection.
Reports and studies suggested that there has been serious problem
related to poor quality of antimalarial drugs in SE Asia, including
countries in the Mekong sub-region emphasising Cambodia in
particular [5,6–10]. This problem has now spread to Africa as the
market for ACTs expands [9]. Counterfeit artemisinin derivatives
and combination therapies have already been described from 6
sub-Saharan African countries [11,12], but to date no large scale
efforts have been undertaken to assess their prevalence and this is
principally due to lack of dedicated laboratory facilities.
Robust, inexpensive, portable, simple to conduct, rapid and
reliable quality control methods to detect poor quality ARTs are
not widely used as they are not readily available. The methods
need to be reasonably accurate and can be carried out with the
minimal use of toxic or flammable reagents. Dr Ying (Shanghai
Institute of Materia Medica of the Chinese Academy of Sciences)
asserts ‘‘If local drug regulators in developing countries are not
equipped with easily portable, operable and low-cost analysis
equipment, it is still very difficult for them to effectively and
efficiently prevent fake drugs against malaria’’ [13].
To address an unmet need for a simple, reliable, affordable test
that can be used at the point of screening with minimal training or
chemical expertise we report here the results of two specific, simple
to use, rapid, reproducible and cost-effective assays that we
developed for the detection of ARTs not only in mono
formulations but also in ACTs. These colorimetric assays utilise
thin layer chromatography (TLC) silica gel sheets and 2, 4
dinitrophenylhydrazine or 4-Benzoylamino-2, 5-dimethoxybenze-
nediazonium chloride hemi (zinc chloride) salt as the reagents to
detect the ARTs.
Materials and Methods
Reagents
Artemisinin and dihydroartemisinin were from Sigma-Aldrich
(Dorset, UK), artesunate (kind gift from GSK) and artemether was
from LGC Standards (Teddignton, UK) were used as reference
compounds. Artemisone was a kind gift from Prof R Haynes,
Laboratory of Chemistry, Hong Kong University. OZ 277 was a
gift from MMV. The Dispro-1, 2, 4, 5-tetraoxane was a gift from
Dr P O’Neil, Department of Chemistry, University of Liverpool,
UK. Thin layer chromatography aluminium sheets Silica gel 60
F254 (Fluka product code: 60743) were from Sigma-Aldrich
(Dorset, UK). Excipients were obtained from the Laboratoire de
Gale´nique, School of Pharmacy, University of Geneva. Drugs
from the WHO essential list were purchased from Sigma-Aldrich.
Other antimalarials drugs are part of the compound library from
the Pharmacology Lab at LSHTM. MininLabH was purchased
from GPHF, Germany.
The reagent 2, 4 dinitrophenylhydrazine (Brady’s reagent,
DNP) was purchased as a powder from Tokyo Chemical Industry
UK Ltd, Oxford, OX4 4GA United Kingdom and the solution
(,0.005 M in ethanol) was from Fluka (product code: 18189).
The reagent 4-Benzoylamino-2, 5-dimethoxybenzenediazo-
nium chloride hemi (zinc chloride) salt (Fast Blue RR salt, FBS)
was obtained from Sigma-Aldrich (Fluka product code: 44680).
DNP is sold as a wet reagent as it is harmful when dry and
toxicological hazards of the FBS have not been fully investigated.
Our assays are conducted with the drop wise addition of a dilute
solution of these reagents thus minimising the hazards.
Methods and Results
The principal of the assays involves dissolving the reference
standard or a pulverized (with a pestle) tablet in methanol, mixing
well and applying a known amount as a spot in a graphite pencil
drawn circle on the TLC sheet followed by dropping either of the
two reagents onto the spot and allowing the reaction to proceed at
room temperature. We tested various supports (such as alumina
coated on plastic sheets, filter paper [WhatmanH product code
1001 125, qualitative, Grade No. 1 - Medium flow rate, medium
porosity, with 11 mm particle retention size]). The most definitive
results in terms of limit of detection by depth of colour seen and
reproducibility were achieved using TLC aluminium sheets Silica
gel 60 F254.
A practical extension of this work is that the identity of each
ART can be determined due to varying polarity. This is achieved
by allowing the spotted sample to be drawn up the TLC sheet via
capillary action using a mixture of chloroform: methanol: acetic
acid (98:2:0.1) described later in this article.
Preparation of samples. Tablets of co-formulations
(amodiaquine/artesunate or dihydroartemisinin/piperaquine or
artemether/lumefantrine) were pulverised with a pestle, methanol
(2 mL) added and solubilisation achieved by placing the mixture in
an ultrasonic bath for 30 s. The mixture was then left on the bench
for a couple of minutes to encourage sedimentation. The reference
compounds (AS, AM, DHA, AE and artemisone: 2.5 mg) were
dissolved in methanol (200 mL). The solutions were mixed
thoroughly (manual shaking or vortex or ultrasonic bath) for 30 s.
Preparations of reagents to spray the plates. DNP
reagent: 2,4-dinitrophenylhydrazine was completely dissolved in
methanolic (80%: w/v) hydrochloric acid (1 M) solution yielding a
final concentration of 0.5 mg/mL.
FBS reagent: Fast Blue RR salt was prepared in water at
5.0 mg/mL and subsequently mixed 1:1 with 80% methanolic 2M
sulphuric acid (H2SO4) solution yielding a final concentration of
2.5 mg/mL.
Targets set for the tests and results. The assays that we
developed selectively detect artemisinin derivatives in
formulations. Our assays use commercially available compounds
and TLC sheets or filter paper to produce two distinct
chromophores depending on the reagent used, i.e. a pink colour
results with DNP or a blue colour with FBS. These assays were
adapted in consideration of the modest resources available in the
developing world. Considerations taken into account prior to
developing these assays are shown in Table 1 (constructed by JR
Ioset and H Kaur). This table includes both target and minimum
acceptable limits. The assays were designed to be used where there
is an absence of specialised laboratories or trained staff.
Validation
A complete validation of the two developed assays was
undertaken in our laboratory following a systematic evaluation:
1. Tested for specificity and validated against the other available
field method (Fast Red Test from GPHF-MiniLabH) [14]. This
includes testing of all major antimalarials currently used on the
market, a wide selection of active principles from the WHO list
of essential drugs as well as a wide range of excipients used in
the pharmaceutical formulation of tablets.
2. Application of the tests to a representative range of tablets from
the field.
3. Confirming the results against high performance liquid
chromatography with photo-diode array detection (HPLC-
PDA) as the gold standard method.
We compared the results of our assays in parallel with the other
available field test (Fast Red Test in the MiniLabH) [14] and found
that our assays specifically detect the artemisinin component only.
Checking the Quality of ACTs
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Our assay is therefore robust, reproducible and sensitive. It has
also been extensively validated using HPLC-PDA the ‘‘reference
standard method’’ to compare our assay. Our assays provide two
user friendly/field friendly methods to monitor the quality of
ARTs and ACT formulations for use in the developing countries.
Determining the specificity of the tests. We compared the
results of our assays with the published colorimetric assay [15,16]
and established that our assays specifically detect the artemisinin
derivatives clinically used as antimalarial drugs. None of the other
antimalarial drugs or a range of commonly used excipients,
antiretroviral drugs or other frequently used drugs from the WHO
essential drugs list such as analgesics or antibiotics are detected
with our assays. It is of special interest to note that artemisinin as
such is not detected in either of our assays.
Other antimalarial drugs. Eleven of the thirty non-ARTs
antimalarial formulations produced a pale to intense yellow,
orange or red colour when tested using the Fast Red Test from the
GPHF-MiniLabH [14]. Additionally the antimalarial compounds -
amodiaquine, mepacrine, primaquine, doxycycline, pyronaridine,
atovaquone and lumefantrine produced the same shade of yellow
colour that results with ARTs. The validation of the DNP and FBS
assays was conducted in parallel with the published methods
devised by Green (both unmodified version for the specific
detection of artesunate [15] and modified version for the detection
of artesunate, artemether and DHA [16]).
These drugs did not produce a colour when tested with our
assays with the exception of primaquine which produced an
orange-brown coloration only when FBS was used as a reagent
and filter paper as the support. This potential confusion is
overcome when TLC and the reagent FBS are used instead of
filter paper as an unambiguous orange colour is produced instead
of the expected blue.
Excipients. A total of thirty excipients were tested for their
potential to react with DNP or FBS to result in the pink or blue
colours that indicate the presence of the ARTs. Most of these
excipients were selected following expert advice (Dr Pascal Furrer,
University of Geneva) from the Handbook of Pharmaceutical
Excipients for their likelihood to be used in the formulation of
tablets, especially the ones manufactured by direct compression of
the material [17]. Furthermore the selected powders are readily
available, cheap and can be easily used to manufacture counterfeit
tablets. A total of seven excipients produced a yellow or orange
reaction using the Fast Red Test from the GPHF-MiniLabH [14].
None of the excipients was found to react with either of the
reagents used in our assays and Figure 1 is typical of the results
achieved (quality of the photograph shown is poor).
Drugs other than ARTs from WHO essential drugs
list. Eighty readily accessible and widely used drugs in malaria
endemic countries were selected from the WHO list of essential
drugs. This selection process ensured that most of the drugs chosen
included the ones that can accidentally or intentionally be sold as
ARTs; other criteria used included testing drugs that are
affordable and have therapeutic efficacy to treat other infectious
diseases in endemic countries. The mode of administration was
also considered as oral drugs were preferentially selected. Of the
80 drugs selected, 29 were not only tested as pure compounds but
also as pharmaceutical formulations (capsules or tablets) supplied
as part of the GPHF-MinilabH.
Table 1. Product profile and minimum acceptable profile assay results.
Criteria Target Minimum acceptable DNP test Fast Blue test
Specificity 100% 98% and no interference
with any antimalarials
98–100% no interference with
antimalarials
99% no interference with
antimalarials
Limit of detection* ,1 mg/mL ,100 mg/mL 1–10 mg (TLC) 50–100 mg (FP) 1–10 mg (TLC) 50–100 mg (FP)
Robustness Not altered by changes in
temp of 10uC
Not altered by small changes in
temp 5uC
Consistent Consistent
Quantitative aspect Quantitative (65%) Qualitative (620%) Semi-quantitative (TLC)** Semi-quantitative (TLC)**
Time needed for assay Less than 5 min Less than 15 min 5–10 min 5–10 min
Time needed for result Instantaneous Less than 8 hours 30–60 min 2–3 h
Amount of material needed for
testing
Less than 1 mg 10 mg 2.5–5 mg 2.5–5 mg
Test support As many as possible At least a very cheap one TLC and filter paper TLC and filter paper
Cost of single assay Less than 2 pence 10 pence consistent consistent
Note: TLC = Thin Layer Chromatography sheet; FP = Filter paper.
* Least amount of substance needed to be detected by the assay, LOD.
**Both qualitative and quantitative results will be needed:
– By definition – counterfeit ARTS preparations don’t contain the active ARTS ingredient and it is most unlikely that one artemisinin derivative
will be substituted by another.
- By definition – substandard drugs may contain a lower dose of active ingredient, may contain ARTS degradation products or be subjected to
other lacks of conformity due to poor good manufacturing practice.
doi:10.1371/journal.pone.0007270.t001
Figure 1. Shows that only artesunate gives a pink colour when
DNP was sprayed onto the spotted artesunate and excipients
onto TLC plate.
doi:10.1371/journal.pone.0007270.g001
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A total of 24 compounds (19 different formulations) were tested
following the experimental conditions described in theGPHF-MinilabH
using the Fast Red test [14,16] and yielded not only yellow to orange
colours but also red or brown or pink that can hinder the detection of
ARTS. Additionally a total of 22 samples (17 drugs) produced
ambiguous coloured reactions (yellow, green or orange colours). A
number of samples are yellow to orange in colour (17 compounds; 15
formulations) before addition of the reagents hence not suitable for
testing using the Fast Red test in the GPHF-MinilabH as they give false
positive results.
Application of our assays to these 80 drugs showed that 4 drugs
produced a colour only with FBS reagent: brown colourations with
furosemide and amphotericin B, violet coloration for silver nitrate
and blue colouration for erythromycin. Hence, erythromycin is the
only compound that reacts in a similar way to ARTS yielding a
blue coloration on both TLC plate and filter paper. The DNP test
does not produce a colour with erythromycin hence ensuring the
specificity of one of the two assays that we developed. All other
active principles, excipients and formulated drugs tested in the
DNP assay, only a pale orange to red coloration was observed with
dexamethasone (reacts immediately), chlorpromazine, and hydro-
cortisone. Whereas a grey-violet spot was observed with silver
nitrate TLC but could unambiguously be discriminated from the
specific colour reaction obtained with ARTS products.
Chromatographic separation of ARTs on TLC and on
HPLC (qualitative vs. quantitative analyses). A useful
extension of this work is that the identity of the ARTs can be
determined based on their varying polarity. This is achieved by
allowing the spotted sample to be drawn up the TLC plate via
capillary action. The solution under investigation is placed as a
spot on the TLC sheet and allowed to elute when placed in the
solvent which travels up the sheet as a result of capillary action.
The ARTs travel at different rates due to differences in their
solubility in the solvent, and due to differences in their attraction to
the silica gel. Following this elution step the colourless ARTS are
detected by spraying with either a methanolic solution of DNP or
FBS which produce the coloured spot.
Modus operandi for the chromatography on thin layer
sheet. A small spot of solution containing the compound was
applied to the TLC sheet, about one centimetre from the base.
The sheet was placed in the tank such that the solvent mixture
(chloroform: methanol: acetic acid [v/v: 98:2:0.1]) was below the
level of the spotted solution and then travels up the sheet. The
sheet was taken out of the solvent before it reaches the top of the
sheet, allowed to dry at room temperature and, sprayed with either
the DNP or FBS reagent to detect the ARTs that migrated at
different rates on the sheet as shown on Figure 2. The HPLC
separation of these ARTs is shown in Figure 3 demonstrating that
the techniques are complementary.
High Performance Liquid Chromatographic (HPLC)
analyses. Separation of the ARTs and artemisinin (Figure 3)
was achieved using HPLC equipment and software from Dionex
(UK) Ltd, Camberley, Surrey, U.K. Separations were carried out
utilising a GENESIS AQ 4 mm column (15064.6 mm,
GRACEVYDACH, Alltech Associates Applied Science Ltd,
Lancashire, UK) eluting with ammonium formate (20 mM,
pH 2.7) and acetonitrile (v/v; 60:40 to 85:15 over 7.0 min)
passing through the UV-photo-diode array detector (UV-PDA;
Dionex model PDA-100) set at 275 nm at a flow rate of 1.0 mL/
min. Peak identity was confirmed by measuring the retention time,
spiking the sample with additional amounts of each compound
and determination of absorbance spectra using the UV-PDA. A
calibration curve of ARTs was generated by Chromeleon (Dionex
software) using known amounts of the standard (0–10 mg/mL) in
methanol. Similarly a calibration curve of amodiaquine (0–
200 mg/mL; but diluted 1:10 to inject on column) was generated.
Applications of our assays to test the quality of retailed
formulations
Modus operandi for the spot test to check for the artemisinin
derivative in a coformulation of amodiaquine/artesunate. A
tablet of the co-formulation amodiaquine/artesunate (150 mg AQ/
50 mg AS) was crushed and dissolved in methanol (10 mL). Circles
were drawn on the TLC sheet using a graphite pencil. The solution of
the reference compound and of the co-formulation in methanol
(10 mL) was then applied onto the circle on using a micropipette or a
graduated capillary. The solution was applied slowly to concentrate the
sample in the given area and each spot is 5 mg AS and 15 mg AQ,
Figure 2. TLC chromatogram of the ARTs; showing the
different rates of travel by artesunate (AS) reference standard
and sample tablet from MiniLabH, dihydroartemisinin (DHA)
and artemether (AM) reference standard and sample tablet
from MiniLabH (Coartem) on silica gel sheets using chloroform:
methanol: acetic acid 98:2:0.1 as an elution system.
doi:10.1371/journal.pone.0007270.g002
Figure 3. Shows the HPLC separation of reference compounds;
artemisinin (5.5 min), artesunate (4.8 min), dihydroartemisin
(5.2 min) and artemether (8.1 min).
doi:10.1371/journal.pone.0007270.g003
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respectively or in the co-formulation. Two reagents were evaluated as
follows:
DNP solution (5 mL; ,0.005 M in ethanol) or FBS solution
(10 mL; 5 mg in 2 M H2SO4) were each dropped onto individual
spots and allowed to stand at room temperature. Solvents (acid
solution without the reagents) were also dropped onto the spots
and methanol was used as the blank. Figure 4 shows the results as
DNP gave a pink colour on the TLC after 10 min, whereas FBS
gave a blue colour after 40 min with intensity varying in function
of the concentration of the ART detected. The depth of colour was
stable for up to 2 weeks. The methanolic solution of AQ/AS was
also analysed using the HPLC method described above to check
the amounts of each component in this co-formulation (Figure 5).
Determining the detection limit of the assays for testing
the amount of ARTs in co-formulations. The limits of
detection for the co-formulations (WINTHROP - artesunate/
amodiaquine, CoartemH-artemether/lumefantrine and Duocortexcin
- dihydroartemisinin/piperaquine) was determined by pulverising each
representative tablet and dissolving in methanol (2 mL). Further
dilutions were carried out to achieve 50% and 10% solutions and
10 mL of each solution was then applied to the TLC plate followed by
either DNP or FBS solutions (10 mL each) and the resulting colour is
shown Figure 6. The depth of colour with DNP was achieved within
10 min and with FBS was achieved within 40 min, and for both the
depth of colour was stable for up to 2 weeks.
Detection of suspect formulations collected from various
countries
Samples of more than 150 artemisinin-based formulations were
collected by our colleagues (working on varying aspects of malaria
research) from 13 countries in Asia, South America and Africa to
check for quality using our assays. Of these samples two were found
not to contain the stated active ingredient: hence they are suspect
(Figure 7A, shows the detection of suspect DHA tablets on sale in
Nigeria). Our attempts to obtain further samples of these tablets
from Nigeria were not successful. We therefore purchased 21
packets (8 tablets in each) of DHA under the brand names
CotecxinH and AlaxinH (manufactured in China and India
respectively) from varying outlets in Nairobi, Kenya. Though these
packets varied in price (210 to 390 Kenyan Shillings) the tablets
were found to contain the stated amounts of the active ingredient.
The other sample which did not give the pink or blue spots in
our assays was from Vietnam which did not contain artesunate the
stated active ingredient.
The quantitative analysis of each tablet was subsequently
carried out using our HPLC method (see the chromatogram;
Figure 7B, above) which indicated that the tablets that failed to
produce colour in our assays did not contain the active
component, DHA.
Discussion
The ability to identify counterfeit or poor quality formulations is
the crucial component of a drug quality assurance system. Many
disease endemic countries do not have regulatory mechanisms or
the technology at their disposal to ensure that the drugs in
circulation are of good quality thus leaving their populations
vulnerable to the risk of counterfeit and substandard drugs. Two
factors prevent the detection of fake anti-malarials at an early stage
of market penetration when intervention has the greatest chance of
success. The first is not having the right tools to be able to detect
counterfeit drugs at the point of screening. The second is the lack
of routine systematic nationwide drug sampling from a complete
range of drug retailers in resource poor countries.
Several analytical techniques using high tech equipment
including liquid chromatography-mass spectroscopy, and high
performance liquid chromatography coupled with photo diode
array detection or electrochemical detection have been developed
Figure 4. Shows TLC results of analysing the ACT- AS/AQ; with
A) DNP and B) FBS as the reagents. Each result was compared with
using solvent alone (1 M HCl for A the DNP test and 2 M H2SO4 for B the
FBS test). BL = methanol, AQ = modiaquine, AS = artesunate and AS/
AQ = the ACT artesunate plus amodiaquine such that each AS spot is
5 mg and each AQ spot is 15 mg.
doi:10.1371/journal.pone.0007270.g004
Figure 5. Shows the HPLC separation of reference standards of
amodiaquine (3.6 min) and artesunate (7.6 min). The dotted line
indicated the peak for amodiaquine when a formulation of AS/AQ is
tested.
doi:10.1371/journal.pone.0007270.g005
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to detect and quantify artemisinins in formulations or biological
fluids. These methods have several merits such as accuracy,
repeatability, specificity and precision but they are expensive,
require access to sophisticated equipment and expertise and
therefore cannot be implemented for routine analysis in the field.
Detection of ARTs on thin layer chromatography (TLC) by
different reagents including iodine, concentrated sulphuric acid or
4-methoxybenzaldehyde [18] has been reported. However these
methods are not specific for ARTS as other compounds react
under the stated experimental conditions resulting in the same or
similar colours. So far one field assay to detect and authenticate
ARTs has been developed by Green et al. (Centre Diseases
Control, Atlanta, USA) and marketed by German Pharma Health
Fund (GPHF-MinliLabH) [14–16]. It is a test tube method that
relies, on the reaction of a commercially available diazonium salt,
Fast Red TR salt, with the ARTs leading to the formation of a
yellow coloured solution which limits its use, especially for ACTs
when the co-formulated antimalarial is itself yellow (amodiaquine,
atovaquone, primaquine, lumefantrine, pyronaridine and doxycy-
cline) and hence give a false positive result.
We have described two colour reaction assays that are specific,
easy to use, robust, inexpensive and rapid, that only detect the
artemisinin component of the formulation and can be used to spot
check the quality of ACTs in the field. Our assays use
commercially available reagents DNP and FBS dissolved in strong
acids. Reaction of the resultant solutions with the ARTs result in
distinctly coloured spots (pink with DNP and blue with FBS). The
experimental conditions required to achieve these results and the
lack of an immediate coloured reaction after pulverisation of the
tablet in DNP or FBS solutions suggest that a decomposition
product of ARTs is involved in the production of the coloured
product. The acid or base transformation of ARTs has been
reported to result in enolate and carboxylates or a, b- unsaturated
decalones [19,20]. It was demonstrated experimentally that diluted
solutions of these mineral acids did not produce the colour nor do
stronger acids including nitric acid and phosphoric acid.
Figure 6. Shows the detection of the artemisinin component from 100% (which is the tablet containing the correct amount of the
active principal ingredient as stated on the packet) down to 50% and 10% (which will imply that the product is substandard or
counterfeit) in formulations of artesunate/amodiaquine (AS/AQ;100% = 50 mg, 50% =25 mg and 10% = 5 mg), artemether/
lumefantrine (AM/LUM, CoartemH; 100% = 20 mg, 50% =10 mg and 10% = 2 mg), and dihydroartemisinin/piperaquine (DHA/PIP,
DuocortexinH; 100% = 40 mgs, 50% =20 mg and 10% = 4 mg).
doi:10.1371/journal.pone.0007270.g006
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Importantly, amounts lower than 10 mg/mL of artemisinin
itself do not yield a coloured product on TLC in either of the
assays. Artemisone, another semi-synthetic artemisinin clinical
candidate, did react positively in both tests. However, the
tetraoxanes (cyclic peroxides) OZ 277 and dispro-1, 2, 4, 5-
tetraoxane did not produce the anticipated pink and blue colours.
It is known that DNP reacts with carbonyl compounds in the
presence of an acid catalyst to produce a coloured product referred
to as a 2,4-dinitrophenylhydrazone. ARTs do not possess a free
carbonyl group (except in the case of the parent artemisinin which
has a lactone carbonyl that does not react with DNP). ARTs are
structurally complex compounds and may undergo a series of
reactions under our acidic experimental conditions to expose
hydroperoxide and carbonyl groups both of which may lead to the
pink and blue coloured products with the reagents DNP and FBS
respectively. However we have found that simple hydroperoxides
such as tert-butyl hydroperoxide do not produce the pink or blue
chromophore. Our attempts to characterise the chemical reaction
mechanisms for the results have indicated a need for in depth
chemical investigation which is beyond the scope of our present
resources.
The validation of the DNP and FBS assays was conducted in
parallel with the published methods devised by Green (both
unmodified version for the specific detection of artesunate [15]
and modified version for the detection of artesunate, artemether
and DHA [16] and sulphuric acid assay [10]).
Limits of detection of the ARTs compounds with the reagents
DNP and FBS in the assays where carried out on TLC sheet as
well as filter paper. A greater amount (2–3 times) of ARTs was
necessary to detect an unambiguous depth of colour on filter paper
compared to that achieved on the TLC sheet. This is probably due
to a larger diffusion and absorption of the compound by the filter
paper. We are able to detect as little as 10% of the declared active
principal ingredient, as stated on the packet, in formulations of
AS/AQ, AM/LUM and DHA/PIP which suggests the DNP and
the FBS. These assays can not only be used to identify counterfeit
medicines but also to get a semi-quantitative measure of the
amounts of ARTS in formulations seen by the depth of colour (see
Figure 6). When less than the stated dose is detected the
formulations should be deemed suspect and not used until
analysed using a medicines quality laboratory which is equipped
with the necessary chromatography systems.
The identity of ARTS can be unambiguously determined by
running a TLC migration with the elution system described above
(see Figure 3). Both DNP and FBS reagents can be used for the
detection of ARTs. Issue of formulations quality can be further
complicated by the fact that exposure of good quality drugs to
light, heat, and humidity through inadequate storage may result in
deterioration and complicate their classification as counterfeit or
substandard. Degradation of rectal artesunate capsules have been
reported to produce DHA, peroxyhemiacetal and deoxyartemisi-
nin as a result of aging [21]. We can detect DHA in our assays and
the possibility of DNP and FBS giving the pink and blue
chromophores with the other degradation products will be
investigated when we acquire them. If the decomposition products
of ARTs [21], were to react with both chemicals, and then
separating the components with migration on TLC will serve to
indicate the quality of the formulations.
Field assays need to be robust as they will inevitably be subject
to changes during their use. Both DNP and FBS are stable
reagents that may be stored at room temperature for longer than 6
months. Solutions of DNP and FBS gave the expected results
when kept for 1–2 months at 20uC in our lab. Samples preparation
is a straight forward process that does not leave much room for
experimental variations. Assays should be conducted using a
reference ARTs drug (not artemisinin) and a negative control
(methanol used for extraction of ARTs in samples) as shown in
Figures 4 and 6.
The assays have been used successfully to identify two samples
which did not contain the stated artemisinin derivative component
(one shown in Figure 7A) from a randomly selected survey of
ARTs tablets collected in various malaria endemic countries -
South East Asia and Africa (Vietnam, Nigeria, Tanzania, Kenya,
Burma, Venezuela and China). These results were corroborated
with HPLC analyses used to confirm the presence or absence of
artemisinin derivative component in the formulations (Figure 7B).
Figure 7. Shows the analyses of CotexcinH samples collected from Nigeria. A) Showing the detection of a fake sample of CotexcinH using
our assays (sample Nig 26 did not give the pink or blue colour with DNP or FBS on TLC when compared with samples Nig 27 and 28 as well as DHA,
the reference active principal ingredient - on the far right hand side). B) Shows the HPLC chromatogram showing the presence of the DHA peak in
samples Nig 27 and 28 but its absence in sample Nig 26 indicated by the dotted arrow at around 4.9 min.
doi:10.1371/journal.pone.0007270.g007
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Conclusion
ACTs are recommended by WHO as first line treatment for
malaria and have been widely implemented in numerous countries
to date. The generalised use of ACTs in conjunction with their
outstanding therapeutic value and high price has put them at risk
of being counterfeited or produced at facilities that are not
accredited. We recently reported on the poor quality of non-ACT
antimalarials from a nationwide study in rural Tanzania [22].
Antimalarial drugs purchased through the retail sector are one of
the key tools used by poor African households to control malaria.
ACTs are expensive and create a significant economic burden on
families so it is essential that the quality and safety of these
medicines is assured. However, drug quality is rarely assessed in
resource poor countries in part due to lack of dedicated laboratory
facilities which are expensive to build, equip and maintain. The
absence of simple, quick, cost effective and reliable tests to detect
fake and substandard products can only facilitate the spread of
suspect ACTs.
We have demonstrated two new robust assays [23] that have
successfully resulted in detecting two counterfeit drugs within a
small scale screening survey of over 100 declared artemisinin-
containing drugs collected from various Asian and African
countries.
These promising results indicate that in a kit format the assays
we have developed provide a useful first test to assure the quality of
the ACTs in resource poor malaria endemic areas and suspect
formulations can then be sent to medicines control laboratories for
comprehensive investigation using state of the art equipment.
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